Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28258477 | 0.92 | KMT2A (0.47) | AKR1C3ALDH1A1POLBKMT2ACYP3A4 | |
| SCHEMBL28242774 | 0.90 | KMT2A (0.46) | AKR1C3ALDH1A1POLBKMT2ACYP3A4 | |
| SCHEMBL5472754 | 0.85 | KMT2A (0.45) | ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7837520 | 0.84 | ALDH1A1 (0.42) | AKR1C3ALDH1A1POLBKMT2AHSD17B10 | |
| SCHEMBL1514526 | 0.82 | HNF4A (0.45) | AKR1C3ALDH1A1POLBKMT2ACYP3A4 | |
| SCHEMBL9513995 | 0.82 | ALDH1A1 (0.58) | AKR1C3ALDH1A1POLBKMT2ACYP3A4 | |
| SCHEMBL1335903 | 0.82 | METAP2 (0.44) | ALDH1A1POLBMETAP2KDM4E | |
| SCHEMBL28084280 | 0.81 | KMT2A (0.43) | AKR1C3ALDH1A1POLBKMT2AMETAP2 | |
| SCHEMBL29378415 | 0.81 | KMT2A (0.68) | AKR1C3ALDH1A1POLBKMT2ACYP3A4 | |
| SCHEMBL8686441 | 0.81 | KMT2A (0.63) | AKR1C3ALDH1A1POLBKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| EP-0946520-B1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORP (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6440969-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | disclosed |
| US-6353103-B1 | STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY. | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-6328793-B1 | FOR USE IN INK JET PRINTING PROCESSES, INCLUDING PIEZOELECTRIC INK JET PRINTING, ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-12-11 | — | — | US | disclosed |
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION. | 2001-11-01 | — | — | US | disclosed |
| US-6235752-B1 | CORTICOTROPIN RELEASING FACTOR; PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-05-22 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6114530-A | ISOQUIOLINAMINES AND PHTHALAZINAMINES USEFUL IN TREATING STRESS RELATED DISORDERES SUCH AS POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-09-05 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0946520-A1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027066-A1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORPORATION (US) | 1998-06-25 | — | — | WO | disclosed |
| US-4058529-A | Polycyclic amino derivatives of pyrrolidone and piperidone | CIBA-GEIGY CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | CRHR1, CRH, CRHR2 | AKR1C3 2513/4885ALDH1A1 3396/4885POLB 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.